Evidence map›Paper›PMID 29016968›Full record

ArticleJournal of the American Medical Informatics Association : JAMIA2017

Formalizing drug indications on the road to therapeutic intent.

Stuart J Nelson, Tudor I Oprea, Oleg Ursu, Cristian G Bologa, Amrapali Zaveri, Jayme Holmes, Jeremy J Yang, Stephen L Mathias, Subramani Mani, Mark S Tuttle and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Medical Informatics Association : JAMIA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. A bottom-up approach to creating an ontology for medication indications.Journal of the American Medical Informatics Association : JAMIA · 2021
    Article
  4. Article
  5. Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs.Journal of the American Medical Informatics Association : JAMIA · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Stuart J NelsonTranslational Informatics Division, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Tudor I OpreaTranslational Informatics Division, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Oleg UrsuTranslational Informatics Division, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Cristian G BologaTranslational Informatics Division, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Amrapali ZaveriInstitute of Data Science, Maastricht University, Maastricht, The Netherlands.
Jayme HolmesTranslational Informatics Division, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Jeremy J YangTranslational Informatics Division, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Stephen L MathiasTranslational Informatics Division, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Subramani ManiTranslational Informatics Division, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Mark S TuttleCenter for Digital Health Innovation, University of California, San Francisco, CA, USA.
Michel DumontierInstitute of Data Science, Maastricht University, Maastricht, The Netherlands.
University of New Mexico · USMaastricht University · NLUniversity of California, San Francisco · US

Funding

Illuminating the Druggable Genome Knowledge Management Center (IDG KMC)U54CA189205 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI OPREA, TUDOR I · 2014 to 2017
$5.7M
NCI NIH HHS U54 CA189205
6 · The paper itself

Abstract

Therapeutic intent, the reason behind the choice of a therapy and the context in which a given approach should be used, is an important aspect of medical practice. There are unmet needs with respect to current electronic mapping of drug indications. For example, the active ingredient sildenafil has 2 distinct indications, which differ solely on dosage strength. In progressing toward a practice of precision medicine, there is a need to capture and structure therapeutic intent for computational reuse, thus enabling more sophisticated decision-support tools and a possible mechanism for computer-aided drug repurposing. The indications for drugs, such as those expressed in the Structured Product Labels approved by the US Food and Drug Administration, appears to be a tractable area for developing an application ontology of therapeutic intent.

Indexed as

Drug LabelingDrug TherapyVocabulary, ControlledDrug RepositioningHumansPrecision MedicineUnited StatesUnited States Food and Drug Administrationdrug indicationsdrug labelstherapeutic intent

Identifiers

PMID29016968
PMCPMC6259666
OpenAlexW2735061578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.